

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

U.S. Application No.	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Group Art Unit	1646
Examiner Name	Chandra, Gyan

Sheet 1 of 5

Attorney Docket No: AGT.10006NP

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
	7,179,465	02-20-2007	Benoit et al.
	7,087,726	08-08-2006	Chuntharapai et al.
	6,787,634	09-07-2004	Benoit et al.
	6,713,609	03-30-2004	Chuntharapai et al.
	6,475,983	11-05-2002	Eid et al.
	6,458,932	10-01-2002	Novick et al.
	6,333,032	12-25-2001	Skurkovich et al.
	6,136,309	10-24-2000	Novick et al.
	5,919,453	07-06-1999	Benoit et al.
	5,889,151	03-30-1999	Mogensen et al.
	5,886,153	03-23-1999	Mogensen et al.
	5,055,289	10-08-1991	Frincke et al.
	4,973,556	11-27-1990	Bove et al.
	4,902,618	02-20-1990	Berg
	4,474,754	10-02-1984	Shimizu et al.
	4,423,147	12-27-1983	Secher et al.
	US20070014724	01-18-2007	Witte et al.
	US20050013799	01-20-2005	Skurkovich et al.
	US20050013800	01-20-2005	Skurkovich et al.
	US20040191840	09-30-2004	Benoit et al.
	US20050013813	01-20-2005	Maroun

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

U.S. Application No.	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Group Art Unit	1646
Examiner Name	Chandra, Gyan

Sheet 2 of 5

Attorney Docket No: AGT.10006NP

	US20040132139	07-08-2004	Escary
	US20030147889	08-07-2003	Tovey
	US20030018174	01-23-2003	Kim et al.
	US20030166228	09-04-2003	Chuntharapai et al.
	US20030021764	01-30-2003	Maroun

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report
	WO 06/037247	04-13-2006		
	WO 05/059106	06-30-2005		
	WO 04/094473	11-04-2004		
	EP 0 325 471 A1	07-26-1989		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
	Alkan and Braun (1986) <i>Ciba Found. Symp.</i> 119: 264-278, entitled "Epitope Mapping of Human Recombinant Interferon alpha Molecules by Monoclonal Antibodies."	
	Baechler et al. (2003) <i>Proc. Nat'l. Acad. Sci. USA</i> 100(5): 2610-2615, entitled "Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus."	
	Banchereau et al. (2004) <i>Immunity</i> 20(5): 539-50, entitled "Autoimmunity through cytokine-induced dendritic cell activation."	
	Båve et al. (2003) <i>J. Immunol.</i> 171: 3296-3302, entitled "FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG."	
	Berg (1984) <i>J. Interferon Res.</i> 4(4): 481-491, entitled "Identification, production, and characterization of murine monoclonal antibody (LO-22) recognizing 12 native species of human alpha interferon."	
	Björck (2004) <i>J. Immunol.</i> 172(9): 5396-5404, entitled "Dendritic cells exposed to herpes simplex virus <i>in vivo</i> do not produce IFN-alpha after rechallenge with virus <i>in vitro</i> and exhibit decreased T cell alloreactivity."	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;"><small>Complete if Known</small></td> </tr> <tr> <td style="width: 50%;">U.S. Application No.</td> <td>10/042,644</td> </tr> <tr> <td>Filing or 371(c) date</td> <td>January 8, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Jacques F. BANCHEREAU</td> </tr> <tr> <td>Group Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>Chandra, Gyan</td> </tr> </table>	<small>Complete if Known</small>		U.S. Application No.	10/042,644	Filing or 371(c) date	January 8, 2002	First Named Inventor	Jacques F. BANCHEREAU	Group Art Unit	1646	Examiner Name	Chandra, Gyan
<small>Complete if Known</small>													
U.S. Application No.	10/042,644												
Filing or 371(c) date	January 8, 2002												
First Named Inventor	Jacques F. BANCHEREAU												
Group Art Unit	1646												
Examiner Name	Chandra, Gyan												
Sheet 3 of 5	Attorney Docket No: AGT.10006NP												

	Blanco <i>et al.</i> (2001) <i>Science</i> 294: 1540-1543, entitled "Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus."	
	Blank <i>et al.</i> (1999) <i>Eur. J. Biochem.</i> 265(1): 11-19, entitled "Identification of a linear epitope of interferon-alpha 2b recognized by neutralizing monoclonal antibodies."	
	Blomberg <i>et al.</i> (2003) <i>Arthritis Rheum.</i> 48(9): 2524-32, entitled "Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus."	
	Braun <i>et al.</i> (2003) <i>J. Autoimmun.</i> 20(1): 15-25, entitled "Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice."	
	Chuntharapai <i>et al.</i> (2001) <i>Cytokine</i> 15(5): 250-60, entitled "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE."	
	Crow and Kirou (2004) <i>Curr. Opin. Rheumatol.</i> 16(5): 541-47, entitled "Interferon-alpha in systemic lupus erythematosus."	
	Crow (2003) <i>Arthritis Rheum.</i> 48(9): 2396-2401, entitled, "Interferon-alpha: a new target for therapy in systemic lupus erythematosus?"	
	Devendra and Eisenbarth (2004) <i>Clin. Immunol.</i> 111(3): 225-233, entitled "Interferon alpha—a potential link in the pathogenesis of viral-induced type I diabetes and autoimmunity."	
	Exley <i>et al.</i> (1984) <i>J. Gen. Virol.</i> 65 (12): 2277-2280, entitled "A comparison of the neutralizing properties of monoclonal and polyclonal antibodies to human interferon alpha."	
	Files <i>et al.</i> (1998) <i>J. Interferon Cytokine Res.</i> 18(12): 1019-24, entitled "A novel sensitive and selective bioassay for human type I interferons."	
	Fish <i>et al.</i> (1989) <i>J. Interferon Res.</i> 9(1): 97-114, entitled "The role of three domains in the biological activity of human interferon-alpha."	
	Foster <i>et al.</i> (2004) <i>J. Immunol.</i> 173(3): 1663-70, entitled "IFN-alpha subtypes differentially affect human T cell motility."	
	Green <i>et al.</i> (2004) <i>Cytokine</i> 26(5): 209-16, entitled "IgG-derived Fc down-regulates virus-induced plasmacytoid dendritic cell (pDC) IFN α production."	
	Gringeri <i>et al.</i> (1999) <i>J. AIDS Hum. Retrovirol.</i> 20(4): 358-70, entitled "Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study)."	
	Gringeri <i>et al.</i> (1996) <i>J. AIDS Hum. Retrovirol.</i> 13(1): 55-67, entitled "Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report."	
	Gringeri <i>et al.</i> (1995) <i>Cell. Mol. Biol. (Noisy-le-grand)</i> 41(3): 381-87, entitled "Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression."	
	Huang <i>et al.</i> (1994) <i>Immunity</i> 1: 469-478, entitled "Islet Expression of IFN- α Precedes Diabetes in Both the BB Rat and Streptozotocin-treated Mice"	
	Hussain <i>et al.</i> (1997) <i>J. Interferon Cytokine Res.</i> 17(9): 559-66, entitled "Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are present in the human population."	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

U.S. Application No.	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Group Art Unit	1646
Examiner Name	Chandra, Gyan

Sheet 4 of 5

Attorney Docket No: AGT.10006NP

	Isenberg and Leckie (2002) <i>Scand. J. Rheumatol.</i> 31(4): 187-91, entitled "Biological treatments for systemic lupus erythematosus."	
	Kirou <i>et al.</i> (2004) <i>Arthritis & Rheumatism</i> 50(12): 3958-3967, entitled "Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus."	
	Mohty <i>et al.</i> (2003) <i>J. Immunol.</i> 171(7): 3385-93, entitled "IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities."	
	Morser <i>et al.</i> (1981) <i>J. Gen. Virol.</i> 53(2): 257-65, entitled "Production and screening of cell hybrids producing a monoclonal antibody to human interferon-alpha."	
	Noll <i>et al.</i> (1989) <i>Biomed. Biochim. Acta</i> 48(1): 165-76, entitled "Production and characterization of four monoclonal antibodies specific for human interferon-alpha-1 and -alpha-2."	
	Overall and Hertzog (1992) <i>Mol. Immunol.</i> 29(3): 391-99, entitled "Functional analysis of interferon-alpha subtypes using monoclonal antibodies to interferon-alpha4a-subtype reactivity, neutralisation of biological activities and epitope analysis."	
	Reyes and Klimpel (1987) <i>Transplantation</i> 43(3): 412-416, entitled "Interferon alpha/beta synthesis during acute graft-versus-host disease."	
	Rönnblom <i>et al.</i> (2003) <i>Autoimmunity</i> 36(8): 463-472, entitled "Role of Natural Interferon- α Producing Cells (Plasmacytoid Dendritic Cells) in Autoimmunity."	
	Rönnblom and Alm (2001) <i>Trends Immunol.</i> 22(8): 427-31, entitled "An etiopathogenic role for the type I IFN system in SLE."	
	Rönnblom and Alm (2001) <i>J. Exp. Med.</i> 194(12): F59-63, entitled "A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus."	
	Santiago-Raber <i>et al.</i> (2003) <i>J. Exp. Med.</i> 197(6): 777-88, entitled "Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice."	
	Schattner <i>et al.</i> , (1988) "Review: Interferons and autoimmunity". <i>Am. J. Med. Sci.</i> 295:532-544.	
	Skurkovich <i>et al.</i> (1997) <i>Cytokine</i> 9(11): 899 (meeting abstract), entitled "The use of antibodies to cytokines (anti-IFN- α , anti-IFN- γ , anti-TNF- α) is an effective method for the treatment of rheumatic diseases-rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PA), and Behcet's syndrome (BS)."	
	Skurkovich <i>et al.</i> (2002) <i>Med. Hypotheses</i> 59(6): 770-80, entitled "Anticytokine therapy—new approach to the treatment of autoimmune and cytokine-disturbance diseases."	
	Staehelin <i>et al.</i> (1981) <i>Proc. Nat'l. Acad. Sci. USA</i> 78(3): 1848-52, entitled "Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons."	
	Stewart (2003) <i>Cytokine Growth Factor Rev.</i> 14(2): 139-54, entitled "Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases."	
	Tsukui <i>et al.</i> (1986) <i>Microbiol. Immunol.</i> 30(11): 1129-39, entitled "A monoclonal antibody with broad reactivity to human interferon-alpha subtypes useful for purification of leukocyte-derived interferon."	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

U.S. Application No.	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Group Art Unit	1646
Examiner Name	Chandra, Gyan

Sheet 5 of 5

Attorney Docket No: AGT.10006NP

	Vancová <i>et al.</i> (2000) <i>J. Interferon Cytokine Res.</i> 20(5): 455-61, entitled "The carboxyterminal domains of human IFN-alpha2 and IFN-alpha8 are antigenically homologous."	
	Vilcek <i>et al.</i> , (1986). In <i>Aids: The epidemic of kaposi's sarcoma and opportunistic infections. "The Role of Interferon in AIDS,"</i> A.E. Friedman-Klein & L.J. Laubenstein, eds. Masson Publishing, New York, New York, 193-198.	
	Viscomi <i>et al.</i> (1999) <i>J. Interferon Cytokine Res.</i> 19(4): 319-326, entitled "Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies."	
	Zagury <i>et al.</i> (1999) <i>Biomed Pharmacother.</i> 53(2): 90-92, entitled "Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum—an adjuvant to antiretroviral tritherapy."	

218769

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached